相似文献
1
Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2.
Br J Clin Pharmacol. 2002 Nov;54(5):540-3. doi: 10.1046/j.1365-2125.2002.01686.x.
2
Quercetin significantly inhibits the metabolism of caffeine, a substrate of cytochrome P450 1A2 unrelated to CYP1A2*1C (-2964G>A) and *1F (734C>A) gene polymorphisms.
Biomed Res Int. 2014;2014:405071. doi: 10.1155/2014/405071. Epub 2014 Jun 15.
3
Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy.
Eur J Clin Pharmacol. 2006 Jan;62(1):23-8. doi: 10.1007/s00228-005-0057-z. Epub 2005 Dec 30.
4
Effects of Common CYP1A2 Genotypes and Other Key Factors on Intraindividual Variation in the Caffeine Metabolic Ratio: An Exploratory Analysis.
Clin Transl Sci. 2019 Jan;12(1):39-46. doi: 10.1111/cts.12598. Epub 2018 Nov 26.
5
Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Clin Pharmacol Ther. 2002 Mar;71(3):141-52. doi: 10.1067/mcp.2002.121788.
6
Omeprazole weakly inhibits CYP1A2 activity in man.
Int J Clin Pharmacol Ther. 1999 Nov;37(11):567-74.
7
The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population.
Clin Pharmacol Ther. 2005 Sep;78(3):249-59. doi: 10.1016/j.clpt.2005.05.012.
8
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.
Eur J Clin Pharmacol. 2007 Jun;63(6):537-46. doi: 10.1007/s00228-007-0288-2. Epub 2007 Mar 17.
9
Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin.
Basic Clin Pharmacol Toxicol. 2006 Oct;99(4):300-4. doi: 10.1111/j.1742-7843.2006.pto_491.x.
10
Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility.
Clin Pharmacol Ther. 2011 Jul;90(1):117-25. doi: 10.1038/clpt.2011.70. Epub 2011 May 18.
引用本文的文献
1
Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study.
Pharmaceuticals (Basel). 2025 Apr 25;18(5):627. doi: 10.3390/ph18050627.
2
Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review.
Croat Med J. 2024 Aug 31;65(4):383-395. doi: 10.3325/cmj.2024.65.383.
3
In Situ Self-Assembling Liver Spheroids with Synthetic Nanoscaffolds for Preclinical Drug Screening Applications.
ACS Appl Mater Interfaces. 2024 May 22;16(20):25610-25621. doi: 10.1021/acsami.3c17384. Epub 2024 May 13.
4
CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.
Sci Rep. 2023 Oct 28;13(1):18507. doi: 10.1038/s41598-023-45752-6.
5
CYP1A2 mRNA Expression Rather than Genetic Variants Indicate Hepatic CYP1A2 Activity.
Pharmaceutics. 2022 Feb 27;14(3):532. doi: 10.3390/pharmaceutics14030532.
6
Review: Influence of the CYP450 Genetic Variation on the Treatment of Psychotic Disorders.
J Clin Med. 2021 Sep 21;10(18):4275. doi: 10.3390/jcm10184275.
7
Pharmacogenetic-Guided Antidepressant Selection as an Opportunity for Interprofessional Collaboration: A Case Report.
Life (Basel). 2021 Jul 9;11(7):673. doi: 10.3390/life11070673.
8
Association Between Maternal Caffeine Consumption and Metabolism and Neonatal Anthropometry: A Secondary Analysis of the NICHD Fetal Growth Studies-Singletons.
JAMA Netw Open. 2021 Mar 1;4(3):e213238. doi: 10.1001/jamanetworkopen.2021.3238.
9
Novel insights on caffeine supplementation, CYP1A2 genotype, physiological responses and exercise performance.
Eur J Appl Physiol. 2021 Mar;121(3):749-769. doi: 10.1007/s00421-020-04571-7. Epub 2021 Jan 5.
10
How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?
Front Genet. 2020 Dec 8;11:491895. doi: 10.3389/fgene.2020.491895. eCollection 2020.
本文引用的文献
1
Polymorphism of CYP450 and cancer susceptibility.
Acta Pharmacol Sin. 2000 Aug;21(8):673-9.
2
G-2964A and C734A genetic polymorphisms of CYP1A2 in Chinese population.
Acta Pharmacol Sin. 2000 Nov;21(11):1031-4.
3
Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2.
Pharmacogenetics. 2001 Jul;11(5):429-35. doi: 10.1097/00008571-200107000-00006.
4
Individual and ethnic differences in CYP2C19 activity in Chinese populations.
Acta Pharmacol Sin. 2000 Mar;21(3):193-9.
5
Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.
Br J Clin Pharmacol. 2000 Feb;49(2):145-51. doi: 10.1046/j.1365-2125.2000.00128.x.
6
Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population.
Jpn J Cancer Res. 1999 Sep;90(9):899-902. doi: 10.1111/j.1349-7006.1999.tb00832.x.
7
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.
Br J Clin Pharmacol. 1999 Apr;47(4):445-9. doi: 10.1046/j.1365-2125.1999.00898.x.
8
Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.
J Biochem. 1999 Apr;125(4):803-8. doi: 10.1093/oxfordjournals.jbchem.a022352.
9
The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin.
Clin Pharmacol Ther. 1997 Jul;62(1):21-8. doi: 10.1016/S0009-9236(97)90148-X.
10
Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test.
Clin Pharmacol Ther. 1994 Apr;55(4):402-11. doi: 10.1038/clpt.1994.49.
Zotero 插件